Switzerland's Tecan saw its sales last year fall 6 per cent as
turnover growth in its genomics/proteomics division failed to
counterbalance declines in drug discovery and diagnostics.
Filtration specialist Pall has seen its second quarter sales and
earnings held back by weak demand in the biopharmaceuticals
industry, particularly in Europe.
The Chinese pharmaceutical industry is still showing above average
growth, but the country's entry into the World Trade Organisation
means that tough times are ahead for manufacturers of active
pharmaceutical ingredients - which...
Nucleic acid specialist Qiagen has reported a strong growth in
sales and profits for the fourth quarter of 2003, providing another
indication that the pharmaceutical and biotechnology industry's
investment in R&D may be recovering.
Israel's Teva Pharmaceutical Industries has reported strong
increases in sales across its branded, generic and active
pharmaceutical ingredient (API) operations in the fourth quarter of
2003, as net income rose by more than a...
In its last set of annual results before being acquired by General
Electric, Amersham of the UK reported lower profits last year as
currency effects bit into the company's bottom line, but saw its
drug discovery unit move into...
Fisher Scientific International has swooped on two companies
providing tools for life sciences companies in a move designed to
boost its product range for research laboratories and
biopharmaceutical production.
Swiss-American laboratory instrument company Mettler-Toledo saw its
fourth-quarter revenues climb 7 per cent to $370 million (€290m)
although the weak dollar accounted for a large proportion of the
increase.
Pharmaceutical, chemical and coatings company Akzo Nobel reported a
9 per cent slide in net income in 2003 but said the result was
better than expected given the difficult operating environment last
year.
UK chemical sector growth, including pharmaceuticals, is forecast
at 3.6 per cent for 2004, outperforming the 2.3 per cent growth
estimated for Europe as a whole, according to a study presented at
the Chemical Industry Association's...
Danish company Chr Hansen saw its revenues slip 4 per cent in its
first quarter, as the impact of the economic downturn and tough
dollar exchange rate was felt across its business units.
Filtration specialist Millipore has reported strong growth in sales
in the fourth quarter of 2003, suggesting that the fortunes of the
biopharmaceutical industry - Millipore's primary customer - may be
on the up.
Healthcare giant Cardinal Health reported revenues up 11 per cent
to $14.1 billion (€11.2bn) in the fourth-quarter of 2003, as a
strong performance in its pharmaceutical manufacturing services,
pharmacy automation and medical product...
A survey has found that difficulties in swallowing pills is
widespread among adults, but is rarely discussed with doctors and
can prevent some people from taking their medicine. The findings
suggest that pharmaceutical companies should...
The amount of pharmaceutical R&D funding headed out-of-house to
research suppliers engaged in drug development work will grow
almost 15 per cent annually for the next five years, nearly double
the anticipated increase in overall...
Filtration and purification specialist Pall has reported a 12.5 per
cent hike in first-quarter sales to $374 million (€310m), with life
sciences putting in a strong showing, up 15.5 per cent to $152
million.
Agilent returns to profit for the first time in two years in the
fourth quarter ended October 31, as cost-cutting compensated for a
modest decline in revenues.
Tecan's third-quarter results reveal a mixed picture across the
group, with proteomics/genomics put in a good good performance but
drug discovery sales fell by a quarter.
PerkinElmer sees the benefit of a cost-cutting effort in its
third-quarter results as net income rises 45 per cent, but
biopharma puts in a lacklustre performance.
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis...
Millipore, which specialises in providing technologies, tools and
services for the discovery, development and production of new
therapeutic drugs, has reported first-quarter 2003 sales of $187
million (€173 million), up 13 per cent...
UK contract pharmaceutical manufacturer and distributor Intercare
Group has reported 2002 turnover of £275.1 million (€406m), an
increase of 27 per cent year-on-year, and pretax profits of £24.6
million, up 15 per cent. The results...
European scientists continue to be strong in areas such as medical
research and chemistry and Europe may produce the highest number of
science graduates but it is lagging behind in biotechnology, still
employs fewer researchers, accounts...
